short-term treatment ( 5 cell doublings ) with the differentiation agent hexamethylene bisacetamide ( hmba ) induced a sharp decrease in tumorigenicity in vivo and loss of a cell surface malignancy marker .
C0007634
cell
C0007589
differentiation